In the first release of its star ratings, only 251 hospitals scored “five out of five stars” on Medicare’s Hospital Compare site.
In the first release of its star ratings on April 16, only 251 hospitals scored “five out of five stars” on Medicare’s Hospital Compare website.
The website is designed to let customers compare hospitals to each other similar to how they would compare hotels or flights, according to the Centers for Medicare and Medicaid Services (CMS).
Hospitals are ranked on a five-star scale, with more stars indicating higher quality care. The star rankings are updated each quarter and are based on patient opinions and not on scientific testing, according to CMS.
Ratings are determined by 11 measures of patient experience, each of which are available for consumers to read on the Hospital Compare site. Those measures are then totaled and a summary star rating combines the 11 measures into a “single, comprehensive metric.”
Medicare doesn’t only rank hospitals by star ratings: Nursing homes, dialysis centers and private Medicare Advantage insurance plans are all ranked on a similar system.
There is some pushback from other hospital ranking organizations. Evan Marks, an executive at Healthgrades, wonders if consumers will use Medicare’s site.
“It’s nice they’re going to try to be more consumer friendly,” Marks told KaiserHealthNews.org. “I don’t see that the new star rating itself is going to drive consumer adoption.” Without a major public relations campaign, consumers may not know about Hospital Compare, he noted.
Related:Hospital ratings: Advancing or obscuring choices?
Many in the healthcare industry worry that customer-based star ratings only tell part of the story. “There’s a risk of oversimplifying the complexity of quality care or misinterpreting what is important to a particular patient, especially since patients seek care for many different reasons,” said the American Hospital Association in a statement to Kaiser Health News.
In order to clarify some confusion about the rankings, Medicare’s website offers some advice: “A one-star rating does not mean you will receive poor care from a hospital. It means that hospitals that received two or more stars performed better on this particular measure of patient experience of care.”
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More